ADVERTISEMENT
Continuing Studies Contribute to CRC Treatment and Prevention
Metagenomics, metabolomics, and immunology studies will continue to open treatment opportunities for patients with colorectal cancer (CRC), new research confirms.
“Dietary interventions may be suitable to modulate the growth of beneficial microbiota in the gut,” the authors reported. “Dysbiosis of the gut microbiome has been associated with the development of CRC. Gut microbiota is involved in the metabolic transformations of dietary components into oncometabolites and tumor-suppressive metabolites that in turn affect CRC development.”
The researchers, using the alpha-bug hypothesis, suggested enterotoxigenic Bacteroides fragilis (ETBF), an oncogenic bacterium, could interact with colonic epithelial cells to actuate the development of CRC , and ultimately alter the colorectal microbiota composition.
Certain alterations in the gut microbiota could potentially be used as a therapeutic approach to preventing and treating CRC, along with such probiotics as Lactobacillus and Bifidobacterium, which proved to hinder CRC growth.
“Escherichia coli, E. faecalis, F. nucleatum, and Streptococcus gallolyticus showed higher abundance whereas Bifidobacterium, Clostridium, Faecalibacterium, and Roseburia showed reduced abundance in CRC patients. Crosstalk between lifestyle, host genetics, and gut microbiota is well documented in the prevention and treatment of CRC,” the authors concluded.
The authors also cautioned, “future studies are required to understand the interaction between gut microbiota and host to the influence and prevention of CRC.”
—Angelique Platas
Reference:
Chattopadhyay I, Dhar R, Pethusamy K, et al. Exploring the role of gut microbiome in colon cancer. Appl Biochem Biotechnol Published January 25, 2021.
